This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
PPARGC1A / Peroxisome proliferator-activated receptor gamma coactivator 1-alpha · Western blot design guide
Design a Western Blot for PPARGC1A
Real validated PPARGC1A Western blot protocols, expected-band and isoform facts, troubleshooting for weak or shifted signal, and recommended anti-PPARGC1A WB antibodies. Everything you need to plan the experiment before you commit precious samples.
Evidence assembled September 2026 · For research use; verify linked source records and product datasheet before use
PPARGC1A Western Blot Experimental Design Guide
Expected bands, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | ~91 kDa | |
| Observed band | ~113 kDa | |
| Gel | 8–10% (standard starting point) | |
| Negative control | Suggested KO / knockdown lysate |
Important caveats
Reasons your observed band may differ from the expected size.
| PTM | Phosphorylated + Acetylated | |
| Caveat | Modification-state controls | |
| Gene-set association | MSigDB Hallmark membership | |
| Isoform | 10 isoform(s) |
Section 1
Real Curated PPARGC1A Western Blot Protocols
The M00236 protocol combines labelled catalog values with standard starting conditions. Published comparisons retain their own sample, reagent and detection scope.
| Sample / lysate | (1) HeLa cell lysate; (2) NIH 3T3 cell lysate; (3) C6 cell lysate (catalog M00236) |
| Gel % | 8–10% (standard starting point) |
| Load | 20–30 µg total protein per lane; optimize for abundance (standard starting point) |
| Transfer | Standard semi-dry transfer; verify efficiency (standard starting point) |
| Membrane | 0.45 µm PVDF (standard starting point) |
| Blocking | 5% milk or 5% BSA in TBST (standard starting point) |
| Primary antibody | M00236; use the WB datasheet starting dilution (standard starting point) |
| Primary incubation | Overnight at 4 °C (standard starting point) |
| Secondary antibody | Species-matched HRP conjugate at validated dilution (standard starting point) |
| Secondary incubation | 1 h at room temperature (standard starting point) |
| Wash | 3 × 5 min in TBST (standard starting point) |
| Detection | ECL; bracket exposures to avoid saturation (standard starting point) |
Section 2
What Is the Expected PPARGC1A Western Blot Band Size?
PPARGC1A is predicted at 91 kDa, while antibody QC shows about 113 kDa; the cause of this difference is not established.
| Band near 113 kDa | Empirical PPARGC1A band reported in reducing lysate blots; confirm identity with controls |
| Band near 91 kDa | Near the predicted full-length mass; identity still requires controls |
| Several bands at different positions | Could reflect annotated isoforms, though their migration has not been established |
| Weak band in whole-cell lysate | Nuclear localization may make nuclear enrichment useful |
💡Expected PPARGC1A appearancePPARGC1A has a predicted mass of 91 kDa, while antibody QC reports a band near 113 kDa in reducing lysates; verify band identity with a positive control and PPARGC1A depletion.
| Predicted full-length mass | 91 kDa is the sequence-based reference; observed migration is near 113 kDa |
| Isoforms 1, NT-7a, B5, B4, B4-8a, B5-NT, B4-3ext, 8a, 9 and 10 | May differ in size; individual masses and resolvable band positions are not supplied |
| N6-acetyllysine at residues 79 and 146 | Documented acetylation; an apparent size effect is not established |
| AMPK phosphorylation at threonine 178 | Documented modification; an apparent size effect is not established |
| Situation | Likely cause | Next action |
|---|---|---|
| No band in lysate | Nuclear PPARGC1A may be poorly represented in the sample | Check a positive-control lysate and try nuclear enrichment |
| Band higher than expected | The reported 113 kDa band migrates above the 91 kDa prediction; the cause is unknown | Compare with a validated positive control and confirm identity by PPARGC1A depletion |
| Band lower than expected | An annotated isoform is possible, but its band position is unknown | Check antibody epitope coverage and confirm identity by PPARGC1A depletion |
| Multiple bands | Annotated isoforms are possible; distinct migration has not been shown | Compare isoform coverage and use PPARGC1A depletion to identify specific bands |
| Weak or no signal | Nuclear localization or low abundance in the sampled lysate | Check a positive control and compare whole-cell with nuclear lysate |
Experiment evidence
Western blot images showing PPARGC1A band
M00236 · PPARGC1A
M00236 · PPARGC1A
M00236 · PPARGC1A
A00236 · PPARGC1A
A00236 · PPARGC1A
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Sample controls for PPARGC1A Western blot
🧪For positive controls for PPARGC1A in Western blot, you can use a positive sample identified through independent validation, since no HPA candidate is supplied.
Positive control: No high/medium HPA tissue identified
Negative control: Suggested KO / knockdown lysate
Loading controls: Run GAPDH, β-actin, and a total-protein stain alongside the samples.
⚠️Feasibility: HPA provides no tissue controls, so positive and negative samples need independent validation.
HPA tissue expression evidence for PPARGC1A
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Higher expression tissues · candidate positive controls from IHC
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| No high/medium HPA tissues identified in the supplied evidence. | ||||
Lower expression tissues · IHC evidence, not confirmed WB-negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| No lower-expression tissue rows available in the supplied evidence. | ||||
Section 3
Advanced PPARGC1A Western Blot Tips
Deeper troubleshooting and optimisation questions for PPARGC1A, answered from its protein features.
How should PPARGC1A band migration be interpreted?
Band shift · Use the separately labelled calculated mass and catalog-observed evidence above. A sequence annotation does not establish an observed migration shift. Verify target identity with orthogonal controls.
Which PPARGC1A isoforms could produce smaller bands?
Isoforms · UniProt lists ten isoforms. Several lack large parts of the canonical 798-residue sequence: isoform 10 lacks residues 100–798, B4-3ext lacks 151–798, NT-7a and B5-NT lack 272–798, and B4-8a and 8a lack 302–798. Check whether your antibody recognizes a region retained in each candidate isoform.
Which PPARGC1A phosphorylation sites matter when comparing conditions?
PTM · UniProt identifies AMPK phosphorylation at Thr178 and Ser539, using canonical sequence coordinates. Compare matched conditions if assessing phosphorylation, and verify any antibody’s site numbering against that convention. These sites do not, by themselves, establish a visible band shift.
UniProt lists N6-acetyllysine at canonical positions 79, 146, 184, 254, 271, 278, 321, 347, 413, 442, 451, 758, and 779. Acetylation is relevant when interpreting modification-sensitive results, but the listed sites alone do not establish that separate Western blot bands will appear.
UniProt lists N6-acetyllysine at canonical positions 79, 146, 184, 254, 271, 278, 321, 347, 413, 442, 451, 758, and 779. Acetylation is relevant when interpreting modification-sensitive results, but the listed sites alone do not establish that separate Western blot bands will appear.
Does this guide establish induction of PPARGC1A?
Induction · No general induction response is established by this guide. A pathway or gene-set association is not evidence of induction in a particular specimen. Verify the relevant treatment and control in a target-specific experiment.
How should transfer be checked for PPARGC1A?
Transfer · Standard workflow guidance: verify transfer efficiency for the intended target size before interpreting a weak signal. Use total-protein assessment and optimize transfer for the membrane, gel and apparatus; the labelled catalog values take precedence.
How should blocking be optimized?
Blocking · Standard workflow guidance: follow the M00236 datasheet where specified. Otherwise compare 5% milk or 5% BSA in TBST; for a phospho-specific assay start with BSA. Optimize background and specific signal with matched controls.
How should PPARGC1A bands be quantified across samples?
Quantitation · Quantify the same defined band or band set across samples and record which isoforms the antibody can recognize. UniProt lists ten isoforms, including several shortened sequences, so combining every detected band could mix distinct forms. For isoform 1, UniProt reports nuclear localization; keep the sampled cell fraction consistent.
Why does PPARGC1A appear near 113 kDa instead of 91 kDa?
Interpretation · The supplied apparent band is about 113 kDa; the predicted mass is 91 kDa. UniProt lists isoforms and modifications, but those features alone do not explain the difference. Check which isoform and antibody epitope your assay detects before assigning the band.
Check the antibody epitope against UniProt’s alternative sequences before assigning a smaller band. Isoform 9 lacks canonical residues 1–127; several other isoforms lack substantial C-terminal regions. The feature list supports these as candidates, but band size alone cannot identify an isoform.
UniProt places isoform 1 in the nucleus and reports it in nuclear PML bodies. When comparing samples, use a consistent extraction procedure and fraction, since those choices affect which cellular material is loaded. The supplied localization applies specifically to isoform 1.
Check the antibody epitope against UniProt’s alternative sequences before assigning a smaller band. Isoform 9 lacks canonical residues 1–127; several other isoforms lack substantial C-terminal regions. The feature list supports these as candidates, but band size alone cannot identify an isoform.
UniProt places isoform 1 in the nucleus and reports it in nuclear PML bodies. When comparing samples, use a consistent extraction procedure and fraction, since those choices affect which cellular material is loaded. The supplied localization applies specifically to isoform 1.
Boster reagents
PPARGC1A Western Blot Antibodies
Catalog antibodies with Western blot application and product-specific WB images. Evaluate suitability with the reported sample, controls and experimental conditions.
Real WB data
Anti-PGC1 alpha PPARGC1A Rabbit Monoclonal Antibody
Cat # M00236
Real WB data
Anti-PPARGC1A Antibody
Cat # A00236
Both listed the supplier antibodies report human, mouse, and rat reactivity and have Western blot images. Their captions document specific lysates and conditions, not performance across all samples or independent validation.
Which to pick: Choose A00236 for the documented mouse liver example at 1 or 2 μg/ml. M00236 has a WB image using HeLa, NIH 3T3, and C6 cell lysates. Match your sample to the closest documented context.
Source: BosterBio PPARGC1A gene-info card — filtered to Western-blot-capable antibodies; each card shows that product's actual WB validation figure.
References
- UniProt Consortium. UniProt entry Q9UBK2.
- Human Protein Atlas. PPARGC1A tissue expression.
- PMC5793202 — target-verified WB comparison
- PMC8087250 — target-verified WB comparison
- PMC11001368 — target-verified WB comparison